Artelo biosciences announces $9.475 million at-the-market private placement to initiate solana treasury strategy, becoming first publicly-traded pharmaceutical company to adopt sol as a core reserve asset

Lead investor bartosz lipiŃski, previously head of engineering at solana labs, will serve as a technical partner cube selected to secure storage, staking, and active defi execution of artelo's digital asset treasury artelo's board approves authorization to expand company's sol treasury management strategy over time solana beach, calif., aug. 04, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market pipe (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million.
SOL Ratings Summary
SOL Quant Ranking